New drug BL-M07D1 targets multiple HER2 cancers in early trial

NCT ID NCT06293898

Recruiting now Disease control Sponsor: SystImmune Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M07D1 (a drug given by IV infusion every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for several hard-to-treat cancers that have HER2 markers.
What could go wrong: This is an early Phase 1 trial, so the main goals are safety and dosing—not yet proof of effectiveness. It may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms breast cancer breast neoplasm cervical cancer endometrial cancer endometrium neoplasm esophageal cancer Esophageal Neoplasms fallopian tube cancer gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma lung cancer lung neoplasm ovarian cancer primary peritoneal carcinoma transitional cell carcinoma urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER BREAST CANCER CERVICAL CANCER ENDOMETRIAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER LUNG CANCER OVARIAN CANCER UROTHELIAL CARCINOMA

Contacts and locations

Locations

Cedars Sinai
RECRUITING

Los Angeles, California, 90211, United States
City of Hope
RECRUITING

Duarte, California, 91010, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Georgia Cancer Center at Augusta University
RECRUITING

Augusta, Georgia, 30912, United States
Karmanos Cancer Institiute
RECRUITING

Detroit, Michigan, 48201, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITING

New York, New York, 10016, United States
NYU Langone Hospital - Long Island Investigational Pharmacy
RECRUITING

Mineola, New York, 11501, United States
Oncology Consultants
RECRUITING

Houston, Texas, 77030, United States
Providence Portland Medical Center
RECRUITING

Portland, Oregon, 97213, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research institute - Lake Nona Florida
RECRUITING

Orlando, Florida, 32827, United States
Scripps Health
NOT_YET_RECRUITING

San Diego, California, 92121, United States
University of Alabama Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of Chicago Medicine
RECRUITING

Chicago, Illinois, 60637, United States
University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.